RESUMEN
This paper describes the synthesis of a series of N-[2-(1-pyrrolidinyl)ethyl]acetamides 1, variously substituted at the carbon adjacent to the amide nitrogen (C1), and related analogues, together with their biological evaluation as opioid kappa agonists. In the first part of the study, the variants in N-acyl, N-alkyl, and amino functions were explored when the substituent at C1 was 1-methylethyl and the optimum was found to be exemplified by 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(1-methylethyl)-2- (1-pyrrolidinyl)ethyl]acetamide (13). Subsequently, racemic or chiral amino acids were used to introduce other alkyl and aryl substituents at C1 of the ethyl linking moiety. A series of potent compounds, bearing substituted-aryl groups at C1, were discovered, typified by 2-(3,4-dichloro-phenyl)-N-methyl-N-[(1R,S)-1-(3-aminophenyl)-2-(1- pyrrolidinyl)ethyl]acetamide (48), which was 5-fold more active as the racemate than 13 in vitro and exhibited potent naloxone-reversible analgesic effects (ED50 = 0.04 mg/kg sc) in a mouse abdominal constriction model.
Asunto(s)
Acetamidas/síntesis química , Analgésicos/síntesis química , Pirrolidinas/síntesis química , Acetamidas/metabolismo , Acetamidas/farmacología , Analgésicos/metabolismo , Analgésicos/farmacología , Animales , Masculino , Ratones , Pirrolidinas/metabolismo , Pirrolidinas/farmacología , Receptores Opioides/efectos de los fármacos , Receptores Opioides kappa , Relación Estructura-Actividad , Conducto Deferente/efectos de los fármacos , Conducto Deferente/metabolismoRESUMEN
This paper describes the synthesis of a series of N-[2-(1-pyrrolidinyl)ethyl]acetamides (1), methylated at C1 and/or C2 of the ethyl linking group, and their biological evaluation as opioid kappa agonists. Conformational analysis of corresponding desaryl analogues 2 suggested that only those compounds capable of occupying an energy minimum close to that of the known kappa agonist N-[2-(1-pyrrolidinyl)cyclohexyl] acetamide U-50488 might possess kappa agonist properties. Starting from chiral amino acids, other alkyl and aryl substituents were introduced at C1 of the ethyl-linking moiety, giving compounds capable of adopting the same conformation as U-50488. The most potent of these, 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] acetamide (8), was 146-fold more active than U-50488 in vitro in the mouse vas deferens model and exhibited potent naloxone-reversible analgesic effects (ED50 = 0.004 mg/kg sc) in an abdominal constriction model.
Asunto(s)
Acetamidas/síntesis química , Analgesia , Analgésicos/síntesis química , Pirrolidinas/síntesis química , Receptores Opioides/efectos de los fármacos , Acetamidas/química , Acetamidas/farmacología , Animales , Femenino , Cobayas , Técnicas In Vitro , Indicadores y Reactivos , Masculino , Ratones , Ratones Endogámicos , Conformación Molecular , Estructura Molecular , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Naloxona/metabolismo , Pirrolidinas/química , Pirrolidinas/farmacología , Receptores Opioides/metabolismo , Receptores Opioides mu , Relación Estructura-Actividad , Conducto Deferente/efectos de los fármacos , Conducto Deferente/fisiología , Difracción de Rayos XRESUMEN
Three novel opioid agonists are described. These compounds were found to bind with high affinity and selectivity to the kappa-opioid receptor. Isolated tissue studies using the field-stimulated mouse vas deferens and guinea-pig ileum preparations confirmed the high agonist potency and naloxone-reversibility of these agents. All three compounds exhibited potent antinociceptive activity in the mouse abdominal constriction model. These compounds should prove useful as tools to investigate kappa-receptor function.